The overproduction of reactive oxygen species (ROS) and consequent oxidative stress
contribute to the pathogenesis of acute and chronic liver diseases. It is now acknowledged …

Non‐alcoholic fatty liver disease is comprised of either simple steatosis (non‐alcoholic fatty
liver) or a more advanced inflammatory and fibrogenic stage (non‐alcoholic steatohepatitis …

Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of
the nuclear hormone receptor superfamily, have been identified as key metabolic regulators …

Objective Obeticholic acid (OCA) has been proved to play potential therapeutic effect on
nonalcoholic steatohepatitis (NASH). Up to now, the study of OCA on NLRP3 inflammasome …

Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) is characterized by intra-hepatocyte
triglyceride accumulation and concomitant involvement of the immune system with …

Transforming growth factor-β (TGF-β)/Smad3 signaling has been shown to play important
roles in fibrotic and inflammatory diseases. However, the role of Smad3 in dyslipidemia and …

Non-alcoholic fatty liver disease (NAFLD) is a global health burden closely linked to insulin
resistance, obesity, and type 2 diabetes. The complex pathophysiology of NAFLD involves …

Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) α and β/δ agonist
that has reached a phase III clinical trial for the treatment of metabolic dysfunction …

Nonalcoholic fatty liver disease (NAFLD) has become globally prevalent and is the leading
cause of chronic liver disease. Although NAFLD is reversible without medical intervention in …

Background and Aims NASH, which is a common clinical condition predisposing to
advanced liver diseases, has become a worldwide epidemic. A large and growing unmet …